Induction of regulatory T cells by infliximab in behçet's disease

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 1, 2011, Pages 476-484

  Sugita, Sunao ^a   Yamada, Yukiko ^a   Kaneko, Satoshi ^a   Horie, Shintaro ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CYCLOSPORIN; CYCLOSPORIN A; INFLIXIMAB; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; ANTIINFLAMMATORY AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE INFLAMMATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; REMISSION; T LYMPHOCYTE ACTIVATION; TOXOPLASMOSIS; UVEITIS; VOGT KOYANAGI SYNDROME; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MENINGOENCEPHALITIS; METABOLISM;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; COLCHICINE; CYCLOSPORINE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; T-LYMPHOCYTES, REGULATORY; TOXOPLASMOSIS, OCULAR; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 79952270370     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5916     Document Type: Article

References (30)

1. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.
2. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight- threatening panuveitis in Behçet's disease. Lancet. 2001;358:295-296.
3. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet. 2001;358:1644.
4. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum. 2005;52: 2478-2484.
5. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51:191-196.
6. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-1164.
7. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845-850.
8. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet's disease. Br J Ophthalmol. 2010;94:284-288.
9. Gul A. Standard and novel therapeutic approaches to Behçet's disease. Drugs. 2007;67:2013-2022.
10. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment. Br J Ophthalmol. In press.
11. Sagawa K, Ito K, Sakaguchi M, et al. Production of IL-8 and the other cytokines by T cell clones established from the ocular fluid of patients with Behçet's disease. Ocul Immunol Inflamm. 1995; 3:63-71.
12. Nakamura S, Sugita M, Tanaka T, et al. In vitro tumor necrosis factor-alpha producibility in peripheral monocytes in patients with Behçet's disease. Nippon Ganka Gakkai Zasshi. 1992;96:1282-1285.
13. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33-39.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299: 1057-1061.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+regulatory T cells. Nat Immunol. 2003;4:304-306.
16. Behçet's Disease Research Committee of Japan. Behçet's disease: guide to diagnosis of Behçet's disease. Jpn J Ophthalmol. 1974; 18:291-294.
17. Hamzaoui K, Hamzaoui A, Houman H. CD4+CD25+regulatory T cells in patients with Behçet's disease. Clin Exp Rheumatol. 2006; 24:71-78.
18. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203:359-370.
19. Valencia X, Lipsky PE. CD4+CD25_FoxP3_ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol. 2007;3:619-626.
20. Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2006;27:110-118.
21. Chen L, Yang P, Zhou H, et al. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi- Harada syndrome. Invest Ophthalmol Vis Sci. 2008;49:3475-3482.
22. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behçet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243:1147-1152.
23. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet's disease. Br J Ophthalmol. In press.
24. Nanke Y, Kotake S, Goto M, et al. Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet's disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol. 2008;18:354-358.
25. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol. 2005;5:343-349.
26. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigenspecific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199:1455-1465.
27. Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA, et al. Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev. 2001;182:122-134.
28. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
29. Yamagiwa S, Gray JD, Hashimoto S, et al. A role for TGF-beta in the generation and expansion of CD4+CD25+regulatory T cells from human peripheral blood. J Immunol. 2001;166:7282-7289.
30. Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170-176.